Once-daily everolimus administration is a further option to improve compliance to immunosuppressive therapy. We randomized 23 stable kidney transplant recipients already on everolimus therapy to receive a single daily morning dose or to continue the twice-daily regimen. The everolimus levels evaluated after 2 weeks showed a slight reduction from 5.13 +/- 1.61 ng/mL at baseline to 4.76 +/- 1.61 ng/mL, which was not statistically significant. After 2 weeks we also evaluated cyclosporine (CsA) levels together with renal function parameters, neither of which showed episodes, any difference between the converted versus twice-daily groups. We did not record any adverse event, such as an infection, an acute rejection episode, or graft loss, over the 6-month study period. Single dosing of everolimus is possible and safe and may achieve better patient compliance to multiple-drug immunosuppressive therapy.
Scheda prodotto non validato
Scheda prodotto in fase di analisi da parte dello staff di validazione
|Titolo:||Conversion of stable kidney transplant recipients from a twice-daily to once-daily everolimus regimen.|
|Citazione:||Carmellini, M., Collini, A., Ruggieri, G., & Bernini, M. (2010). Conversion of stable kidney transplant recipients from a twice-daily to once-daily everolimus regimen. TRANSPLANTATION PROCEEDINGS, 42(4), 1312-1313.|
|Appare nelle tipologie:||1.1 Articolo in rivista|
File in questo prodotto: